GSK India managing director Sridhar Venkatesh outlines how the company navigated pandemic-related turbulence and “stuck its neck out” to ensure uninterrupted supplies of key drugs. The executive also discusses launch prospects for products including Xevudy in India and an intent to “refresh” the company’s vaccines portfolio.
Sridhar Venkatesh moved from Singapore to take over the top job as managing director at GlaxoSmithKline Pharmaceuticals Ltd. in India bang in the middle of the pandemic in 2020.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The Swiss biotech firm could go public on the NASDAQ later this year, and points to other preclinical dealmaking in the space to back its strategy.
As ADCs continue to be a growth area globally, a new US-based venture with novel platform technology has emerged from stealth mode with $20m in funding.
The collaboration, supported by UK and Singapore government agencies, aims to develop an mRNA-based, needle-free universal bird flu vaccine suitable for use in a pandemic.
Sanofi's Paul Hudson and Novartis's Vas Narasimhan claim that while Europe is home to some of the most important biopharma companies in the world, its position is in jeopardy.
Sanofi's Paul Hudson and Novartis's Vas Narasimhan claim that while Europe is home to some of the most important biopharma companies in the world, its position is in jeopardy.
Paul Stoffels, the J&J research veteran who helmed Galapagos during a crucial period, will retire upon the appointment of a new CEO as the company continues its latest transformation.
The biotech reported Phase I multiple-ascending dose data for its obesity drug for the second time in a week, but its safety and tolerability do not offset concerns about relatively unimpressive weight reduction.
